

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AL	116	4,753,894	28.06.88	Frankel et al.			
	117	4,935,341	19.06.90	Bargmann et al.			
	118	4,943,533	24.07.90	Mendelsohn et al.			
	119	4,975,278	04.12.90	Senter et al.			
	120	5,169,774	08.12.92	Frankel et al.			
	121	5,288,477	22.02.94	Bacus, S.			
	122	5,359,046	25.10.94	Capon et al.			
	123	5,367,060	22.11.94	Vandlen et al.			
	124	5,401,638	28.03.95	Carney et al.			
	125	5,464,751	07.11.95	Greene et al.			
	126	5,578,482	26.11.96	Lippman et al.			
	127	5,604,107	18.02.97	Carney et al.			
	128	5,663,144	02.09.97	Greene et al.			
	129	5,705,157	06.01.98	Greene, M. L.			
	130	5,720,937	24.02.98	Hudziak et al.			
	131	5,720,954	24.02.98	Hudziak et al.			
	132	5,725,856	10.03.98	Hudziak et al.			
	133	5,726,023	10.03.98	Cheever et al.			
	134	5,728,687	17.03.98	Bissery, M.			
	135	5,747,261	05.05.98	King et al.			
	136	5,770,195	23.06.98	Hudziak et al.			
	137	5,772,997	30.06.98	Hudziak et al.			
	138	5,776,427	07.07.98	Thorpe et al.			
	139	5,801,005	01.09.98	Cheever et al.			
	140	5,834,229	10.11.98	Vandlen et al.			
	141	5,837,243	17.11.98	Deo et al.			
	142	5,837,523	17.11.98	Greene et al.			
	143	5,840,525	24.11.98	Vandlen et al.			
	144	5,846,538	08.12.98	Cheever et al.			
	145	5,856,110	05.01.99	Vandlen et al.			
	146	5,859,206	12.01.99	Vandlen et al.			
	147	5,869,445	09.02.99	Cheever et al.			
	148	5,876,712	02.03.99	Cheever et al.			
	149	5,877,305	02.03.99	Huston et al.			
	150	5,908,835	01.06.99	Bissery, M.			
	151	5,910,486	08.01.99	Curriel et al.			

Examiner

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
12/17 ↓	152	5,922,845	13.07.99	Deo et al.			
	153	5,939,531	17.08.99	Wels et al.			
	154	5,968,511	19.10.99	Akita et al.			
	155	5,977,322	02.11.99	Marks et al.			
	156	5,985,553	16.11.99	King et al.			
	157	6,015,567	18.01.00	Hudziak et al.			
	158	6,028,059	22.02.00	Curiel et al.			
	159	6,054,297	25.04.00	Carter et al.			
	160	6,054,561	25.04.00	Ring			
	161	6,096,873	01.08.00	Schaefer et al.			
	162	6,123,939	26.09.00	Shawver et al.			
	163	6,165,464	26.12.00	Hudziak et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
12/17 ↓	164	0,616,812 A1	28.09.94	EPO			
	165	711,565	26.08.98	EPO			
	166	2,761,543B2	04.06.98	JAPAN (TRANSLATION ATTACHED)			
	167	2,895,105B2	24.05.99	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	168	3-240498	25.10.91	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	169	5-117165	14.05.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	170	5-170667	09.07.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	171	5-213775	24.08.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	172	5-317084	03.12.93	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	173	7-59588	07.03.95	JAPAN (ENGLISH ABSTRACT ATTACHED)			
	174	95,006,982B2	30.01.95	JAPAN (ENGLISH ABSTRACT AND CLAIMS)			
	175	WO 00/61185	19.10.00	PCT			
	176	WO 89/06692	27.07.89	PCT			
	177	WO 92/10573	25.06.92	PCT			
	178	WO 93/12220	24.06.93	PCT			
	179	WO 93/21232	28.10.93	PCT			
	180	WO 93/21319	28.10.93	PCT			
	181	WO 94/28127	08.12.94	PCT			
	182	WO 95/16051	15.06.95	PCT			
	183	WO 95/17507	29.06.95	PCT			
	184	WO 95/28485	26.10.95	PCT			

Examiner

Amie Hill

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
ALH ↓	185	WO 96/18409	20.06.96	PCT				
	186	WO 97/04801	13.02.97	PCT				
	187	WO 97/20858	12.06.97	PCT				
	188	WO 97/27848	07.08.97	PCT				
	189	WO 97/38731	23.10.97	PCT				
	190	WO 98/45479	15.10.98	PCT				
	191	WO 99/31140	24.06.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

192	Baselga et al., "Anti HER2 Humanized Monoclonal Antibody (MAB) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts" <u>Proceedings of ASCO-13th Annual Meeting</u> (Abstract #53), Dallas, TX 13:63 (Mar 1994)
193	Baselga et al., "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications" <u>Oncology</u> 11(3 Suppl 2):43-48 (Mar 1997)
194	Baselga et al., "Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents" <u>Annals of Oncology</u> (abstract #010) 5(Suppl. 5) (1994)
195	Baselga et al., "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" <u>Cancer Research</u> 58:2825-2831 (July 1998)
196	De Santis et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)
197	DiFiore et al., "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells" <u>Science</u> 237(4811):178-182 (Jul 10, 1987)
198	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)
199	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)
200	Fleiss, JL <u>Statistical Methods for Rates and Proportions</u> , 2nd edition, New York, NY:Wiley pps. 13-17 (1981)
201	Gemzar (gemcitabine HCL), "Product Information - PDR" (2000)
202	Green et al., "Preclinical Evaluation of WR-151327: An Orally Active Chemotherapy Protector" <u>Cancer Research</u> 54(3):738-741 (Feb 1, 1994)
203	Guy et al., "Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease" <u>Proc. Natl. Acad. Sci. USA</u> 89(22):10578-10582 (Nov 15, 1992)
204	Hynes and Stern, "The biology of erbB-2/neu/HER-2 and its role in cancer" <u>Biochimica et Biophysica Acta</u> 1198(2-3):165-184 (Dec 30, 1994)
205	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)
206	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)

Examiner

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group	Mean	SD	95% CI
Control	1.00	0.00	1.00
Intervention	1.00	0.00	1.00

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Anne L. Hillman

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
Aut	224	5,804,396	08.09.98	Plowman			12.10.94


Examiner

Amel Heller

Date Considered

11/17/2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

1642

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
RLH	225	6,417,168	09.07.02	Greene et al.			

Examiner

Ann C. Holleran

Date Considered

Oct 21, 2002

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1467R2	Serial No. 09/602,812
		Applicant Adams et al.	
		Filing Date 23 Jun 2000	Group 1642

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
ALH	236	2002/0076695	Ross, J.			
ALH	237	2002/0155527	Stuart et al.			
ALH	238	5,514,554	Bacus, S.			
ALH	239	5,571,894	Wels, W. et al.			
ALH	240	5,587,458	King, C. et al.			
ALH	241	5,783,404	Koski, R.			
ALH	242	5,846,749	Slamon et al.			
ALH	243	5,856,089	Wang et al.			
ALH	244	5,882,864	An et al.			
ALH	245	5,925,519	Jensen et al.			
ALH	246	5,994,071	Ross et al.			
ALH	247	6,270,765	Deo et al.			
ALH	248	6,333,348	Vogel et al.			
ALH	249	6,358,682	Jaffee et al.			
ALH	250	6,395,272	Deo et al.			
ALH	251	6,403,630	Dannenberg et al.			
ALH	252	6,458,356	Arakawa et al.			
ALH	253	6,512,097	Marks et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No	
ALH	254	1,006,194	EPO				
ALH	255	412,116	EPO				
ALH	256	444,181	EPO				
ALH	257	494,135	EPO				
ALH	258	502,812	EPO				
ALH	259	554,441	EPO				
ALH	260	656,367	EPO				
ALH	261	WO 01/05425	PCT				
ALH	262	WO 01/09187	PCT				
ALH	263	WO 01/20033	PCT				
ALH	264	WO 01/21192	PCT				
ALH	265	WO 01/32155	PCT				
ALH	266	WO 87/07646	PCT				
ALH	267	WO 89/10412	PCT				
ALH	268	WO 91/02062	PCT				

Examiner <i>Anne L. Holleran</i>	Date Considered <i>11/19/03</i>
----------------------------------	---------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1467R2	Serial No. 09/602,812
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.	
		Filing Date 23 Jun 2000	Group 1642

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
ALH	269 WO 91/05264	18.04.91	PCT			
ALH	270 WO 93/03741	04.03.93	PCT			
ALH	271 WO 93/16185	19.08.93	PCT			
ALH	272 WO 96/07321	14.03.96	PCT			
ALH	273 WO 96/16673	06.06.96	PCT			
ALH	274 WO 96/40789	19.12.96	PCT			
ALH	275 WO 97/00271	03.01.97	PCT			
ALH	276 WO 98/02463	22.01.98	PCT			
ALH	277 WO 98/16628	23.04.98	PCT			
ALH	278 WO 98/18489	07.05.98	PCT			
ALH	279 WO 98/33914	06.08.98	PCT			
ALH	280 WO 99/55367	04.11.99	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ALH	281	Agus et al., "Differential Anti-Tumor Effects of Targeting Distinct Epitopes of the Her-2/neu Extracellular Domain in Xenograft Models of Prostate Cancer." <u>Proceedings of the American Association for Cancer Research Annual Meeting (Abstract #4570) 41:719 (Mar 2000)</u>
ALH	282	Agus et al., "Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-Dependent and -Independent Human Xenograft Models" <u>Cancer Research 59:4761-4764 (1999)</u>
ALH	283	American Cancer Society Textbook of Clinical Oncology, Murphy et al., 2nd edition, Atlanta:American Cancer Society pps. 126-127 (1995)
ALH	284	Ching, K., "Role of c-erb B gene family in prostate cancer" <u>Dissertation Abstracts International 55(11):4738-B (May 1995)</u>
ALH	285	Curnow, R., "Clinical experience with CD64-directed immunotherapy. An overview" <u>Cancer Immunology and Immunotherapy 45(3-4):210-215 (Nov-Dec 1997)</u>
ALH	286	Curti, B., "Physical barriers to drug delivery in tumors" <u>Critical Reviews in Oncology-Hematology 14(1):29-39 (Feb 1993)</u>
ALH	287	Ezeh et al., "Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor- α and epidermal growth factor in vivo" <u>Journal of Neurobiology 37(2):199-210 (Nov 5, 1998)</u>
ALH	288	Gibson et al., "A novel method for real time quantitative RT-PCR" <u>Genome Research 6(10):995-1001 (Oct 1996)</u>
ALH	289	Gura, T., "Systems for identifying new drugs are often faulty" <u>Science 278(5340):1041-1042 (Nov 7, 1997)</u>
ALH	290	Heid et al., "Real time quantitative PCR" <u>Genome Research 6(10):986-994 (1996)</u>
ALH	291	Jain, R., "Barriers to drug delivery in solid tumors" <u>Scientific American 271(1):58-65 (Jul 1994)</u>
ALH	292	James et al., "Phase II Trial of the Bispecific Antibody MDX-H210 (anti-Her2/Neu X anti-CD64) Combined With GM-CSF in Patients With Advanced Prostate and Renal Cell Carcinoma That Express Her2/Neu." <u>British Journal of Cancer (Abstract #56) 78:19 (1998)</u>

Examiner <i>Ann C. Sullivan</i>	Date Considered 11/17/03
------------------------------------	-----------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1467R2	Serial No. 09/602,812
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Adams et al.	
		Filing Date 23 Jun 2000	Group 1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Anne L. Holleran

Date Considered

11 | 19 | 03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.